Share your videos with the world

Sign Up | Log In | Help  

   
 
Search // biopharmaceutical
Results 1-6 of 6 for ' biopharmaceutical ' (0 seconds)
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. To view the multimedia release go to: https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Categories // Miscellaneous 
Added: 1905 days ago by MultiVuVideos
Runtime: 3m35s | Views: 342 | Comments: 0
Not yet rated
 

 

 

The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running. The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it? The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia). To view the multimedia release go to: http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Categories // Miscellaneous 
Added: 2361 days ago by MultiVuVideos
Runtime: 3m36s | Views: 466 | Comments: 0
Not yet rated
 

 

 

Patients and scientists from across the country are featured in the latest “From Hope to Cures” ad campaign launched today by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading biopharmaceutical researchers and biotechnology companies. This continuation of PhRMA’s “From Hope to Cures” campaign, first launched in January 2014, highlights the value biopharmaceutical innovation provides to patients, society and the economy. The latest ad campaign, featuring print, radio and digital advertising, highlights the stories of patients who benefit from the medicines developed by biopharmaceutical companies and the scientists who work every day to develop life-saving treatments and cures. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350552-phrma-from-hope-to-cures/
Added: 2721 days ago by MultiVuVideos
Runtime: 2m5s | Views: 522 | Comments: 2
Not yet rated
 

 

 

Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™. To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
Added: 3369 days ago by MultiVuVideos
Runtime: 3m28s | Views: 716 | Comments: 1
Not yet rated
 

 

 

AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange. With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. A global enterprise that serves patients in more than 170 countries, AbbVie launches with an estimated $18 billion in annual revenues and a strong commitment to creating shareholder value through long-term growth potential and the continuation of the company’s history of shareholder dividends. To view Multimedia News Release, go to http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new-biopharmaceutical-company
Categories // Business  News and Politics 
Added: 3510 days ago by MultiVuVideos
Runtime: 1m6s | Views: 1085 | Comments: 1
Not yet rated
 

 

 

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
Added: 4448 days ago by MultiVuVideos
Runtime: 2m16s | Views: 5993 | Comments: 1
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2022 ClipMoon.com. All rights reserved.